Gapping up
In reaction to strong earnings/guidance:
- BCO +19.6%, TUP +16.8%, AAN +12.8%, FEYE +12.1%, AMD +11.2%, CYH +10.7%, SMG +10.4%, CAR +9.8%, AGYS +9.3%, UMC +9%, ACCO +8.8%, TENB +8.8%, FLOW +7.9%, SHOP +6.8%, VIV +5.9%, BYD +5.6%, BG +5.6%, SBUX +5.5%, BXP +4.9%, GRMN +4.7%, IMAX +4.4%, GM +4.1%, CHRW +3.5%, BE +3.4%, AXS +3.3%, CSGP +3.2%, OC +3.2%, SF +3.2%, DT +3.1%, EQR +3%, ROL +2.9%, WING +2.8%, UNM +2.6%, ALKS +2.5%, OVV +2.4%, HA +2.3%, SYX +2.3%, JNPR +2.2%, MPWR +2.2%, RDY +2.2%, AMED +2%, WH +2%, RXN +2%, RIO +2%, BXMT +2%, ETN +1.9%, SNY +1.6%, ETR +1.6%, ARCB +1.5%, AER +1.5%, BA +1.5%, LSCC +1.4%, SLAB +1.4%, FTV +1.3%, GE +1.3%, ENB +1.2%, DXCM +1%, SSNC +1%
Other news:
- LB +19.7% (announces $400 mln in annualized cost reductions; has reopened most Bath & Body Works and Victoria's Secret stores in North America), SSL +12.7% (sells sixteen air separation units located in Secunda to Air Liquide)
- BANF +7.5% (to join S&P SmallCap 600)
- FBIO +7% (announces publication of study on targeted next generation sequencing for newborn screening and Menkes disease)
- CCC +5.5% (signs definitive agreement to combine with CPA Global)
- IAA +4.4% (to join S&P MidCap 400)
- CRTX +4.3% (presents data linking P. gingivalis infection to cardiovascular disease severity and Alzheimer's disease)
- REXR +4.1% (to join S&P MidCap 400)
- CRS +3.8% (to join S&P SmallCap 600)
- DLX +3.7% (to join S&P SmallCap 600)
- INO +3.4% (granted FDA orphan drug designation for INO-3107 for treatment of recurrent respiratory papillomatosis)
- HRZN +3.3% (declares dividends of $0.10/sh for Oct, Nov and Dec)
- ATUS +3.1% (to sell 49.99% of Lightpath fiber enterprise business)
- HRB +3.1% (releases preliminary results for the recent US tax season)
- HA +2.3% (launches offering of Enhanced Equipment Trust Certificates)
- TSLA +1.7% (S&P upgrades to 'B+' on strengthening business position)
- GILT +1.6% (receives cellular backhaul project award for Kcell)
- AGI +1% (announces construction decision on La Yaqui Grande Project)
Analyst comments:
- EGLE +4.2% (upgraded to Buy from Hold at DNB Markets)
- CSGP +3.3% (upgraded to Overweight from Underweight at JP Morgan)
- SBLK +2.5% (upgraded to Buy from Hold at DNB Markets)
- HSBC +2.1% (upgraded to Buy from Hold at Investec)
- ROK +2.1% (upgraded to Neutral from Sell at Rosenblatt)
- MIST +1.1% (upgraded to Outperform from Perform at Oppenheimer)